Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06765187 · ClinicalTrials.gov registry record
A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire
A clinical trial, sponsored by Sanofi.
- Completed
- Registry status
- 1,007
- Enrollment target
NCT06765187: Completed study, sponsored by Sanofi.
NCT06765187 is a clinical trial that has completed, run by Sanofi. The registered enrollment target is 1,007 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06765187 has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- 1,007 participants
- Enrollment target
Study Summary
This study aims to assess patient-reported experiences following trivalent recombinant influenza vaccine (RIV3) vaccination using the Vaccinees' Perception of Injection (VAPI) questionnaire, identify factors related to vaccine choice and future vaccination intentions in each case, and assess the cross-validity of VAPI, by establishing magnitude of correlations to EuroQol 5 Dimensions, 5 Levels (EQ-5D-5L) domains. Participants will need approximately 30 minutes to complete the self-administered online survey. Individuals will be recruited via a U.S. retail chain partner that offers the RIV3 vaccine as part of their routine influenza vaccination program
Primary Outcome
The VAPI questionnaire covers four sections. The first section collects information around pre-vaccination, including motivation, hesitancy, concerns, and routine changes. The second section focuses on the vaccination moment, specifically on vaccination experience regarding pain, anxiety, satisfaction with the vaccination platform, and information received. The third section focuses on post-vaccination experiences. The fourth section captures the overall vaccination experience in terms of tolera
Interventions
- BIOLOGICAL Trivalent Recombinant Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,007 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2025-12-22 |
What the finished NCT06765187 record still lists
NCT06765187 is an observational study that tracks outcomes without assigning an intervention. Its 1,007 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Trivalent Recombinant Influenza Vaccine is the first listed.
NCT06765187 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06765187 about?
NCT06765187 is a clinical study titled "A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire". This study aims to assess patient-reported experiences following trivalent recombinant influenza vaccine (RIV3) vaccination using the Vaccinees' Perception of Injection (VAPI) questionnaire, identify factors related to vaccine choice and future vaccination intentions in each case, and assess the cro...
What is the current status of trial NCT06765187?
This trial is currently completed. The enrollment target is 1,007 participants. The study started on 2024-11-18. Estimated completion is 2025-12-22.
What interventions are being tested in trial NCT06765187?
The interventions under investigation include: Trivalent Recombinant Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06765187?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07191782 · 1,008 participants · NA
Examining the Efficacy of the PRAISE With Coaching Program
- NCT04389632 · 1,006 participants · Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- NCT06207864 · 1,001 participants · NA
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI